Loading...
•
Jun 30, 2022
Sangamo Q2 2022 Earnings Report
Reported business highlights and financial results for the second quarter of 2022.
Key Takeaways
Sangamo Therapeutics reported a net loss of $43.2 million, or $0.29 per share, for the second quarter of 2022. The company is advancing its clinical-stage programs and preparing to complete dosing of the first cohort in its TX200 program.
Fabry disease program is progressing into the Phase 1/2 study’s expansion phase and planning for Phase 3 is underway.
Sickle cell disease program transitioned back to Sangamo, with manufacturing activities advancing in anticipation of dosing in Q3 and Phase 3 planning progressing.
Hemophilia A program is expected to resume dosing in Q3 2022, with a pivotal data read-out expected in late 2023 or early 2024.
Renal Transplant Rejection program received Orphan Medicinal Product Designation from the European Commission and is progressing towards anticipated Q3 dosing.
Forward Guidance
Sangamo continues to expect total operating expenses in the range of approximately $320 million to $350 million on a GAAP basis, and non-GAAP total operating expenses in the range of approximately $280 million to $310 million in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...